A low dose of an experimental messenger-RNA-based SARS-CoV-2 vaccine triggered an immune response in animals, and studies in people might start next month, says German biotech firm CureVac. The technology is similar to that used in a vaccine from Moderna, which reported preliminary results from studies in mice and humans this week.
Coronavirus vaccine triggers immune response in animals
Sign up for FBR SmartBrief
Biomedical Research News
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.